Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Selectis Health (GBCS) Minority Interest (2017 - 2021)

Historic Minority Interest for Selectis Health (GBCS) over the last 7 years, with Q1 2021 value amounting to -$187395.0.

  • Selectis Health's Minority Interest rose 763.81% to -$187395.0 in Q1 2021 from the same period last year, while for Mar 2021 it was -$187395.0, marking a year-over-year increase of 763.81%. This contributed to the annual value of -$198045.0 for FY2020, which is 320.33% up from last year.
  • According to the latest figures from Q1 2021, Selectis Health's Minority Interest is -$187395.0, which was up 763.81% from -$198045.0 recorded in Q4 2020.
  • In the past 5 years, Selectis Health's Minority Interest ranged from a high of -$183339.0 in Q4 2017 and a low of -$205751.0 during Q2 2020
  • For the 5-year period, Selectis Health's Minority Interest averaged around -$199311.8, with its median value being -$201372.0 (2018).
  • Its Minority Interest has fluctuated over the past 5 years, first crashed by 809.59% in 2018, then skyrocketed by 763.81% in 2021.
  • Over the past 5 years, Selectis Health's Minority Interest (Quarter) stood at -$183339.0 in 2017, then fell by 8.1% to -$198182.0 in 2018, then decreased by 3.24% to -$204599.0 in 2019, then rose by 3.2% to -$198045.0 in 2020, then increased by 5.38% to -$187395.0 in 2021.
  • Its Minority Interest stands at -$187395.0 for Q1 2021, versus -$198045.0 for Q4 2020 and -$201440.0 for Q3 2020.